AZ’s Fasenra shows promise in hypereosinophilic syndrome
admin 5th April 2019 Uncategorised 0The drug is AstraZeneca’s first respiratory biologic. More: AZ’s Fasenra shows promise in hypereosinophilic syndrome Source: News
read moreThe drug is AstraZeneca’s first respiratory biologic. More: AZ’s Fasenra shows promise in hypereosinophilic syndrome Source: News
read moreDaiichi Sankyo nabbed a $6.9 billion antibody drug conjugate deal with AstraZeneca as it appointed a new CEO; Keytruda became the first PD-1/L1 to land a Chinese nod in untreated non-small cell lung cancer; Chi-Med rolled out positive data for
read moreThe expansion will use BRACAnalysis CDx to identify germline BRCA mutations. More: Myriad, AstraZeneca and MSD expand collaboration Source: News
read moreThe less frequent dosing gives both patients and oncologists more flexibility, helping to free up hospitals. More: EU approves new dosing schedule for MSD’s Keytruda Source: News
read more© 1994 - 2024 B.M. Pharmaceuticals